Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

321
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
321
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

523
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
523
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

242
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
242
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

72
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
72
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

1.0K
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
1.0K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

549
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
549

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IVUS-guided wiring using the deep vein as a landmark (IDEAL) technique for treating chronic total occlusions in peripheral artery disease.

CVIR endovascular·2025
Same author

Efficacy of Adaptive Servo-Ventilation in Worsening Heart Failure.

International heart journal·2025
Same author

Temporary use of leadless pacemaker as a bridge to cardiac resynchronisation therapy: a case report of fulminant myocarditis.

European heart journal. Case reports·2025
Same author

Usefulness of Respiratory Stability Time-Guided Management to Prevent Readmission of Chronic Heart Failure Patients at Home: A Multicenter, Single-Arm, Open-Label Clinical Study (ITMETHOD-HF-III).

Journal of clinical medicine·2025
Same author

Correction: Contemporary optimal therapeutic strategy with escalation/de-escalation of temporary mechanical circulatory support in patients with cardiogenic shock and advanced heart failure in Japan.

Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs·2025
Same author

Gender difference and outcomes in HeartMate 3 left ventricular assist device support: Results from the J-MACS registry.

Journal of cardiology·2025

Related Experiment Video

Updated: Mar 8, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K

Who Needs Longer Tolvaptan Treatment?

Koichiro Kinugawa1, Takayuki Inomata, Naoki Sato

  • 1Second Department of Internal Medicine, University of Toyama.

International Heart Journal
|January 24, 2017
PubMed
Summary

Tolvaptan, a V2 receptor antagonist, improved heart failure symptoms within 14 days for most patients. Further benefits were seen in longer-treated groups, though some patients may not respond.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Related Experiment Videos

Last Updated: Mar 8, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Tolvaptan, a vasopressin receptor 2 (V2) antagonist and aquaretic agent, is approved in Japan for heart failure with volume overload.
  • Understanding patient characteristics and treatment effectiveness is crucial for optimizing heart failure management.

Purpose of the Study:

  • To investigate patient characteristics and the effectiveness of tolvaptan in heart failure patients.
  • To compare outcomes between patients treated for 14 days or less (14DS) and those treated for 15 days or longer (15DL).

Main Methods:

  • Retrospective analysis of the SMILE study data.
  • Categorization of patients into 14DS and 15DL treatment groups.
  • Assessment of patient characteristics and clinical outcomes, including congestive symptoms and specific physical signs.

Main Results:

  • The 15DL group exhibited characteristics of low cardiac output and diuretic resistance.
  • Significant improvement in congestive symptoms was observed within 14 days for both 14DS and 15DL groups.
  • Statistically significant, albeit subtle, further improvements in edema, pulmonary congestion, dyspnea, and auscultation findings were noted in the 15DL group after two weeks, suggesting potential non-responders.

Conclusions:

  • Tolvaptan demonstrates effectiveness in improving heart failure symptoms within 14 days.
  • Longer treatment duration may offer additional subtle benefits, particularly in patients with diuretic resistance.
  • Further research, including biomarker identification and prospective randomized studies, is needed to identify responders and validate findings.